HCM - HUTCHMED  DRC logo

HUTCHMED DRC

HCM

HUTCHMED (China) Limited develops and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases. Its portfolio includes drugs for various cancers and conditions, with global operations and collaborations with major pharmaceutical firms.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$1,224today

Score Overview

1 Year
Score
Net Growth-96.10%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-0.15%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score5.3
Net Growth109.19%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth54.19%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth52.87%
Net Trend20%
Net Income Consistency
Rev Growth154.13%
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth52.87%
Net Trend20%
Net Income Consistency
Rev Growth154.13%
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where HUTCHMED DRC has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. HCM does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 14.28โ€”
1 Year2025-10-22
$ 15.11-5.49%
5 Years2021-10-22
$ 32.17-55.61%
10 Years2016-10-21
$ 11.6722.37%
All Time2016-03-17
$ 13.406.57%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 549M$ 17M$ 1.37B
2025$ 549M$ 458M$ 1.36B
2024$ 630M$ 37M$ 836M
2023$ 837M$ 100M$ 886M
2022$ 426M-$ 360M$ 630M
2021$ 356M-$ 194M$ 1.01B
2020$ 227M-$ 125M$ 435M
2019$ 204M-$ 106M$ 217M
2018$ 214M-$ 74M$ 300M
2017$ 241M-$ 26M$ 358M
IPO2016$ 216M$ 11M$ 103M
HCM - HUTCHMED  DRC logo

HUTCHMED DRC fundamental performance

Between 2020 and 2025, revenue grew from $ 227M to $ 549M and net income went from -$ 125M to $ 458M. Revenue increased in 2 of those 5 years; net income in 2.

Between 2016 and 2025, revenue grew from $ 216M to $ 549M and net income grew from $ 11M to $ 458M. Revenue increased in 50% of the years measured; net income in 20%.

HUTCHMED DRC currently holds a 5-year HDB Score of 5.3 out of 10. How the HDB Score is calculated.

Membership

Explore HCM with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies